N/A
Completed N=2,714
Study to Document Treatment Patterns and to Evaluate Leuprolide and Alternative Therapeutic Approaches to the Treatments of Advanced Prostate Cancer
Source: ClinicalTrials.gov NCT01081873 ↗Enrolled (actual)
2,714
Serious AEs
4.5%
Results posted
Mar 2012
Primary outcomePrimary: Effectiveness Parameter for Staging of Prostate Cancer: Metastases at Each Visit — 782; 59; 45; 28 participants
Summary
Document treatment patterns and evaluate LUCRIN / LUCRIN-TRIDEPOT® (Leuprolide) and alternative therapeutic approaches to the treatment of advanced prostate cancer during normal clinical practice and in accordance with the terms of the Belgian marketing authorization and reimbursement conditions.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Effectiveness Parameter for Staging of Prostate Cancer: Metastases at Each Visit |
782; 59; 45; 28; 74; 33 | — |
| PRIMARY Effectiveness Parameter for Screening or Recurrence of Prostate Cancer: Mean Prostate-specific Antigen (PSA) at Each Visit |
62.16; 12.95; 6.23; 8.01; 8.41; 8.88 | — |
| PRIMARY Effectiveness Parameter: the Number of Participants With a Complete or Partial Response, Stable Disease, or Progressive Disease Following Treatment at Each Visit |
525; 496; 402; 668; 347; 401 | — |
| PRIMARY Effectiveness Parameter for Prognosis: the Number of Participants With a Survival Prognosis of > 10 Years, 5 - 10 Years, 1 - 5 Years, 6 - 12 Months, and < 6 Months |
395; 132; 100; 91; 113; 75 | — |
| PRIMARY Treatment Patterns for Prostate Cancer Treatments: Number of Participants at Each Visit Who Took Lucrin/Lucrin Tridepot, Luteinizing Hormone-releasing Hormone (LHRH) Agonists, Anti-androgens, or Other Drug Treatments, or Who Had Surgery or Radiotherapy. |
2028; 1011; 817; 640; 969; 540 | — |
| SECONDARY Safety Parameter: Number of Participants Reporting Serious Adverse Events (SAEs) |
121 | — |
| SECONDARY Epidemiological Data: Mean Weight |
77.36 | — |
| SECONDARY Epidemiological Data: Mean Age |
75.39 | — |
| SECONDARY Epidemiological Data: Race |
59; 2154; 4 | — |
| SECONDARY Epidemiological Data: Tumor Staging - Among Participants With a Positive Biopsy, the Number of Participants With Adenocarcinoma Tissue or Other Tissues Recorded for the Positive Biopsy. |
2269; 9; 1 | — |
| SECONDARY Epidemiological Data: PSA at Baseline |
13.66 | — |
| SECONDARY Epidemiological Data: Tumor Staging (Positive or Negative) Via a Rectal Examination, Prostate Biopsy, Echograph, or Magnetic Resonance Imaging (MRI) Test. |
2045; 2355; 1806; 102; 439; 9 | — |
| SECONDARY Epidemiological Data: the Number of Participants With Tumor Stages T0, T1, T2, T3, and T4. |
30; 223; 614; 1215; 220 | — |
| SECONDARY Epidemiological Data: Node Staging - the Number of Participants With a Positive or Negative Computerized Tomography (CT) Scan or Magnetic Resonance Imaging (MRI) Test |
374; 1212 | — |
| SECONDARY Epidemiological Data: Node Staging - the Number of Participants With a N0 or N1 Stage at Baseline. |
1296; 360 | — |
| SECONDARY Epidemiological Data: Bone Scan at Baseline |
497; 1353 | — |
| SECONDARY Epidemiological Data: Metastasis Staging (M0 or M1) at Baseline |
1373; 501 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with advanced prostate cancer who have been prescribed Lucrin/ Lucrin-Tri-depot or any other treatment with local reimbursement guidelines; Patients willing to consent to data being collected and provided to Abbott Laboratories.
Exclusion Criteria
- Contraindications according to the Summary of Product Characteristics (SPC).
Data sourced from ClinicalTrials.gov (NCT01081873). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.